Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function

Persechini, Marie-Laure; Gennero, Isabelle; Grunenwald, Solange; Vezzosi, Delphine; Bennet, A.; Caron, Philippe

doi:10.1007/s11102-014-0596-3

Cited by 23 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, asymptomatic tumor growth was detected by postpartum MRI in 3 of 27 pregnancies in the largest retrospective study (3) and in two of six cases by routine MRI performed at 6 months of pregnancy. Interestingly, the tumors in those two cases were mixed GH/PRLsecreting adenomas (38).…”

Section: Effect Of Pregnancy On Tumor Growth In Acromegalymentioning

confidence: 94%

“…During this period, rising estrogen levels would induce a state of GH resistance as reflected by a significant decline in circulating IGF-1, although a compensatory rise in GH-N levels has not been uniformly observed during this period (37,38).…”

Section: The Somatotrophic Axis During Normal Pregnancymentioning

confidence: 98%

“…Contemporary experience has usually shown a rather stable clinical course of disease activity during pregnancy in most patients (2,3,4,5,38,46,50,51). Such favorable outcome is likely to reflect the overall improvement in both diagnosis and treatment of patients with acromegaly in the last decades.…”

Section: Effect Of Pregnancy On Clinical and Hormonal Activity Of Acrmentioning

confidence: 99%

“…Those symptoms may also be caused by tumor enlargement due to bleeding/infarction (apoplexy) (53), 'expansion after shrinkage' of the tumor after the withdrawal of somatostatin analogs (2,38) and even by the physiological enlargement of the pituitary gland during pregnancy (56). The distinction among true proliferative growth of the tumor, tumor enlargement due to bleeding/ infarction and pregnancy-induced pituitary enlargement should be well established through patient's history and pituitary imaging for proper therapeutic management.…”

Section: Effect Of Pregnancy On Tumor Growth In Acromegalymentioning

confidence: 99%

“…Newborns from women who interrupted medical treatment before or at the beginning of pregnancy have been typically normal (2,3,4,5,38). Also, children born from women with acromegaly who discontinued treatment during pregnancy have been shown to have normal general health status at 2, 3 and 6 years of age (73,74,75), as well as IQ scores similar to those born from normal women or from women with prolactinoma (76).…”

Section: Effect Of Acromegaly and Its Treatment On Fetal Developmentmentioning

confidence: 99%

See 4 more Smart Citations

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and pregnancy: a contemporary review

Abucham

Bronstein

Rodrigues

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Although fertility is frequently impaired in women with acromegaly, pregnancy is apparently becoming more common due to improvement in acromegaly treatment as well as in fertility therapy. As a result, several studies on pregnancy in patients with acromegaly have been published in recent years adding new and relevant information to the preexisting literature. Also, new GH assays with selective specificities and the knowledge of the expression of the various GH genes have allowed a better understanding of somatotrophic axis function during pregnancy. In this review, we show that pregnancy in women with acromegaly is generally safe, usually with tumoral and hormonal stability. Although the paucity of data limits evidence-based recommendations for preconception counseling and pregnancy surveillance, controlling tumor size and hormonal activity before pregnancy is highly recommended to ensure better outcomes, and surgical control should be attempted when feasible. Treatment interruption at pregnancy confirmation has also proven to be safe, as drugs are not formally allowed to be used during pregnancy. Drug exposure (somatostatin analogs) during early or whole pregnancy might increase the chance of a lower birth weight. Aggressive disease is uncommon and may urge individual decisions such as surgery or drug treatment during pregnancy or lactation.Correspondence should be addressed to J Abucham

show abstract

Section: Effect Of Pregnancy On Tumor Growth In Acromegalymentioning

confidence: 94%

Section: The Somatotrophic Axis During Normal Pregnancymentioning

confidence: 98%

Section: Effect Of Pregnancy On Clinical and Hormonal Activity Of Acrmentioning

confidence: 99%

Section: Effect Of Pregnancy On Tumor Growth In Acromegalymentioning

confidence: 99%

Section: Effect Of Acromegaly and Its Treatment On Fetal Developmentmentioning

confidence: 99%

See 3 more Smart Citations

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and pregnancy: a contemporary review

Abucham

Bronstein

Rodrigues

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Early pregnancy IGF‐I and placental GH and risk of epithelial ovarian cancer: A nested case‐control study

Schöck

Fortner

Surcel

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF-I) signaling may promote ovarian tumor development by exerting mitotic, anti-apoptotic, and pro-angiogenic effects. During pregnancy, maternal production of IGF-I is regulated by placental growth hormone (GH). Parity is an established protective factor for ovarian cancer, however, no prior study has evaluated placental GH and IGF-I in pregnancy and epithelial ovarian cancer (EOC). Prior prospective studies on the association between IGF-I and EOC in non-pregnant populations were inconclusive and did not address associations in subtypes of EOC. Among members of the Finnish Maternity Cohort and the Northern Sweden Maternity Cohort we identified 1,045 EOC cases, diagnosed after recruitment (1975-2008) and before March 2011, and 2,658 individually matched controls. Placental GH and IGF-I were measured in serum from the last pregnancy before EOC diagnosis or selection as control. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals [CI] for tertiles and a doubling of hormone concentrations. Higher IGFI was associated with a non-significant decrease in risk for invasive (ORT3 vs. T1: 0.79 [0.62-1.02]; ptrend=0.07) and endometrioid tumors (ORT3 vs. T1: 0.55 [0.28-1.07]; ptrend=0.07). The protective association between higher IGF-I levels and risk of invasive EOC was stronger in analyses limited to women aged <55 years at diagnosis (ORT3 vs. T1: 0.74 [0.57-0.96]; ptrend=0.03). Our study provides the first data on placental GH and IGF-I in pregnancy and EOC risk overall and by subtype. Our data suggest higher IGF-I levels in pregnancy may be associated with lower risk of invasive and endometrioid EOC.

show abstract

The expression level of mir‐21‐3p in platelet‐rich plasma: A potential effective factor and predictive biomarker in recurrent implantation failure

Babian

Salehpour

Nazari

et al. 2022

Molecular Reproduction Devel

View full text Add to dashboard Cite

Recurrent implantation failure (RIF) is the most important complication associated with in vitro fertilization (IVF). Despite the good quality of the transferred embryo, the success rate is rather disappointing. Therefore, predictive biomarkers for implantation are critical to making decisions about transferring high-quality embryos or cryopreserving them for cycles with a higher chance of implantation. Recently, intrauterine infusion of autologous platelet-rich plasma (PRP) has been proposed to increase the endometrial receptivity in RIF patients. PRP is rich in both growth factors and microRNAs (miRNAs). We investigated the possible association of mir-21-3p, mir-21-5p, mir-494-3p, mir-145-5p, and insulin-like growth factor-I (IGF-I) levels in PRP and platelet-poor plasma (PPP) samples with the pregnancy outcomes in RIF patients. The miRNA expression level and IGF-I concentration were assessed using real-time PCR and chemiluminescence methods respectively. Mir-21-3p was upregulated in PRP samples of the pregnant group in comparison to the nonpregnant group. There was no difference in the expression of mir-21-3p in PPP samples of these groups. The concentration of IGF-I was higher in PRP and PPP samples of the nonpregnant in comparison to the pregnant group. Receiver-operating characteristic curve analysis showed that mir-21-3p can be a valuable biomarker for the prediction of pregnancy chance in RIF patients treated with PRP.

show abstract

Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function

Abstract: In women with normal somatotroph function, IGF-1 levels decrease in the first trimester of pregnancy without changes in GH or IGF-BP3 levels. These results confirm liver resistance to GH as a consequence of the physiological increase of estrogens during the first trimester.

Cited by 23 publications

References 24 publications

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and pregnancy: a contemporary review

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and pregnancy: a contemporary review

Early pregnancy IGF‐I and placental GH and risk of epithelial ovarian cancer: A nested case‐control study

The expression level of mir‐21‐3p in platelet‐rich plasma: A potential effective factor and predictive biomarker in recurrent implantation failure

Contact Info

Product

Resources

About